BiotechTube

AGMB-129

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Fibrostenotic Crohn's Disease

Conditions

Fibrostenotic Crohn's Disease

Trial Timeline

Aug 6, 2025 → Sep 15, 2025

NCT ID
NCT07118878

About AGMB-129

AGMB-129 is a phase 1 stage product being developed by Agomab Therapeutics for Fibrostenotic Crohn's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT07118878. Target conditions include Fibrostenotic Crohn's Disease.

Hype Score Breakdown

Clinical
6
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT07118878Phase 1Completed
NCT06397508Phase 1Completed

Competing Products

1 competing product in Fibrostenotic Crohn's Disease

See all competitors
ProductCompanyStageHype Score
AGMB-129 + PlaceboAgomab TherapeuticsPhase 2
33